Nelson Advisors: How Next Generation Sweat Sensors Could Turn a Skin Patch into a Continuous Health Lab

Nelson Advisors

6 minutes ago

13 min read

Nelson Advisors: How Next Generation Sweat Sensors Could Turn a Skin Patch into a Continuous Health Lab

For most of medical history, if you wanted to know what was happening inside a person's body, you had to break the skin. Blood is the gold standard for almost every biomarker clinicians care about, and getting at it means needles, vials, laboratories and waiting. Even the most celebrated success in wearable biosensing, the continuous glucose monitor, still relies on a filament pushed under the skin to sample interstitial fluid.

Sweat has always been the obvious alternative. It sits right at the surface, it is produced almost continuously, and it carries a remarkably rich cargo of molecules that leak across from the blood and from the sweat glands themselves: electrolytes, metabolites, hormones, proteins, drugs and their breakdown products. The challenge was never whether sweat contains useful information. It was whether anyone could build a device small enough, sensitive enough and stable enough to read that information reliably, on a moving human being, for days at a time.

That challenge is now being solved. A new generation of sweat sensors can continuously track multiple biomarkers from perspiration at once, and the trajectory of the research suggests that a simple wearable patch could eventually help monitor hydration, stress, fatigue, metabolic health and even early signs of disease.

This article looks at where the technology has come from, what the latest breakthroughs actually do, what still stands in the way, and what it might mean for healthcare, sport and the wearables industry.

Why sweat and why now

Sweat is not just salty water. Eccrine sweat glands, of which the average adult has somewhere between two and four million, are fed by a dense network of capillaries. As sweat is produced, small molecules diffuse or are actively transported from the blood plasma into the gland, so the fluid that reaches the skin surface reflects, with some lag and some distortion, what is circulating in the body. Sodium and chloride tell you about fluid and electrolyte balance. Lactate reflects both local muscle metabolism and the gland's own activity. Glucose, urea, ammonia and creatinine appear at concentrations related to their blood levels. Cortisol, adrenaline, noradrenaline, oestradiol and other hormones cross over at picomolar or nanomolar concentrations. Cytokines, which signal inflammation, have also been detected.

Medicine has actually used sweat for a long time, in one narrow form. The sweat chloride test has been the definitive diagnostic for cystic fibrosis since the 1950s, and it works by stimulating a small patch of skin with a drug called pilocarpine, delivered by a weak electrical current, then collecting and analysing the resulting sweat. That technique, iontophoresis, is now a foundational trick in modern sweat sensors, because it means a patch can generate sweat on demand from a sedentary wearer rather than waiting for them to exercise or overheat.

What changed in the last decade is the convergence of several fields. Flexible electronics learned how to print conductive circuits on soft, skin-conforming polymers. Microfluidics, the science of moving tiny volumes of liquid through channels narrower than a hair, matured to the point where sweat could be routed, timed, mixed with reagents and sampled in nanolitre quantities. Electrochemistry provided enzyme-based and antibody-based sensing electrodes that could be miniaturised. Wireless power and near-field communication removed the need for batteries. And smartphones gave every wearer a reader, a display and a link to the cloud.

The landmark moment is usually traced to 2016, when a team at the University of California, Berkeley published a fully integrated wearable that measured glucose, lactate, sodium and potassium in sweat simultaneously, alongside skin temperature, and transmitted the data wirelessly. It proved that multiplexed, real-time sweat analysis was possible. A decade of increasingly sophisticated devices has followed, and the pace is accelerating.

What the latest sensors can actually do

Three recent developments give a good sense of how far the field has come.

A patch that regenerates itself and runs for three weeks

One of the most persistent problems in bio-sensing is fouling. When a sensing surface binds its target molecule, it eventually saturates or becomes coated with proteins and debris, and its signal drifts. This is why most research prototypes only worked for hours or, at best, a day or two, and why they were mostly tested on athletes in laboratories rather than on ordinary people going about their lives.

In May 2026 a team at the University of California, Irvine, led by Rahim Esfandyarpour, reported in Nature Biomedical Engineering a wireless, battery-free patch that addresses this directly. The device monitors four biomarkers at once: cortisol as an indicator of stress, glucose as a window on metabolism, lactate as a measure of exertion, and urea as a marker of kidney function. It is powered by near-field communication from a smartphone or smartwatch held near the skin, and it uses a biocompatible hydrogel activated by an induced electromagnetic field to generate sweat without the wearer having to exercise.

The crucial innovation is in situ regeneration. Low-voltage electrical pulses periodically release the molecules bound to the sensing surface, restoring the sensor's sensitivity. The team demonstrated continuous operation for 21 days without signal degradation, across variations in temperature and pH. In Esfandyarpour's words, the device can "refresh itself, generate sweat and be worn for long durations outside of laboratory or clinical settings." That last phrase is the important one. Three weeks of stable, unsupervised monitoring is the difference between an academic demonstration and something that could plausibly be prescribed.

Stress, measured in three hormones

Stress is one of the most requested and least well-measured aspects of health. Consumer wearables infer it from heart rate variability and skin conductance, which are indirect proxies. The biochemical reality is more specific: the body's stress response runs on two partly separate systems, the hypothalamic-pituitary-adrenal axis, whose output is cortisol, and the sympathetic nervous system, whose output is adrenaline and noradrenaline.

Wei Gao's group at Caltech has spent years building sweat sensors for exactly these molecules. Their earlier work produced a low-cost cortisol patch, using laser-engraved graphene electrodes, that could track the hormone's daily rhythm and its spike in response to stressors. In 2025 they described a microfluidic biosensor, sometimes referred to as a "stressomic" platform, that measures cortisol, adrenaline and noradrenaline together at picomolar sensitivity. It uses iontophoresis to draw out sweat, capillary burst valves to meter it, and gold nanodendrite electrodes for electrochemical immunoassays.

The human studies produced a finding that makes the case for multiplexing better than any engineering argument could. Different stressors engaged different arms of the stress response. Emotional stress, induced by provocative imagery and sound, raised noradrenaline without significantly moving cortisol. High-intensity exercise raised both. A single-biomarker device would have missed half the picture. As Gao put it, the results "reinforced how different stressors engage different arms of the stress response."

Hormones across the reproductive cycle

The same group has also shown, in a 2023 Nature Nanotechnology paper, a patch that wirelessly tracks oestradiol in sweat. This uses aptamers, short strands of synthetic DNA that fold around a target molecule much as an antibody does, coupled to gold nanoparticles and MXene films for sensitivity. Automatic microfluidic valves control how much sweat reaches the sensor, and the device calibrates itself in real time using pH, salt concentration and skin temperature. In testing it tracked the roughly tenfold rise in oestradiol between menstruation and ovulation. Because oestradiol rises before ovulation, the obvious applications are fertility planning, IVF timing and the management of hormone replacement therapy, all of which currently depend on clinic blood draws.

Taken together, these three lines of work show sensors that are multiplexed, wireless, battery-free, self-calibrating, self-regenerating and able to work on someone sitting at a desk. That is the definition of next-generation.

The five frontiers: hydration, stress, fatigue, metabolism and disease

It is worth taking each of the promised applications in turn, because they sit at very different points on the path from laboratory to clinic.

Hydration is the most mature use case and the one that has already reached consumers. Sweat rate and sweat sodium concentration vary enormously between individuals, by a factor of five or more, which is why generic hydration advice is so often wrong for a given person. Epicore Biosystems, a spin-out from John Rogers' laboratory at Northwestern University, commercialised a microfluidic patch with Gatorade as the Gx Sweat Patch. It is a single-use, colorimetric device: channels fill with sweat during a workout, dyes change colour in proportion to volume and chloride, and a smartphone camera reads the result to produce a personalised fluid and electrolyte replacement plan. The company has since extended the same approach into a connected, reusable form for industrial and military workers at risk of heat stress. Nix Biosensors offers a similar electronic patch for athletes. None of these are medical devices, but they have established the manufacturing, regulatory and consumer groundwork that the more ambitious products will build on.

Stress, as described above, is where the most compelling multi-biomarker science is being done. The clinical opportunity is significant. Cortisol dysregulation is implicated in depression, anxiety, post-traumatic stress disorder, burnout and Cushing's and Addison's diseases, and a continuous, objective measure would transform how these conditions are assessed and how treatments are titrated. There are also large occupational markets, from pilots and surgeons to soldiers and astronauts, where an early warning that someone's physiological stress load is climbing has real safety value.

Fatigue is closely related and draws on several of the same signals. Lactate has long been the exercise physiologist's marker of anaerobic threshold, and sweat lactate, though it correlates imperfectly with blood lactate, tracks changes in exertion in real time. Combined with sodium loss, glucose depletion, cortisol and skin temperature, a patch could give athletes, endurance workers and clinicians a composite view of physical and metabolic strain. There is also growing interest in using the same sensors for chronic fatigue, post-viral conditions and recovery monitoring after illness, where objective measures are scarce.

Metabolic health is where the commercial stakes are highest and the science is most contested. Continuous glucose monitoring is already a multi-billion-pound market, dominated by needle-based devices from Abbott and Dexcom, and it is spreading from diabetes management into wellness. A non-invasive sweat glucose sensor would be the holy grail. The problem is that sweat glucose sits at roughly one hundredth of the blood concentration, is easily contaminated by skin, and its relationship to blood glucose varies with sweat rate and between individuals. Most experts believe sweat glucose can reliably show trends and relative changes but will struggle to match the absolute accuracy that regulators demand for insulin dosing decisions. The more likely near-term role is as one signal among several, alongside lactate, ketones, urea and hormones, in a broader picture of metabolic function.

Early signs of disease is the most speculative frontier and the most exciting. The UC Irvine team included urea specifically as a marker of kidney function. Other groups have built integrated sweat sensors for multiple liver disease biomarkers, and sweat has been proposed as a matrix for detecting inflammatory cytokines, uric acid in gout, levodopa and other drugs in Parkinson's patients, and even tumour-associated markers. The deep attraction is that a patch worn continuously could detect a drift away from a person's own baseline long before symptoms appear, turning diagnosis from an event into a background process. This is precisely the kind of longitudinal, personalised, high-frequency data that today's blood testing regime, built around occasional snapshots, cannot provide.

What still stands in the way

It would be easy to write the rest of this post as breathless prediction. The more useful thing is to be clear about the obstacles, because they determine which companies and which applications will win.

Sweat is a messy sample. Its composition changes with sweat rate, skin temperature, the site on the body, the time of day, hydration status and what the person ate. Biomarkers can be diluted, concentrated or reabsorbed on their way to the surface. A sensor that reads a molecule accurately in the lab may still produce a misleading number in the field if it does not simultaneously measure and correct for these confounders. This is why the best modern devices integrate pH, temperature, sodium and sweat rate sensors alongside the target analytes, and why self-calibration is now regarded as essential rather than optional.

The sweat to blood question is unresolved for many analytes. For sodium and chloride, sweat is arguably the more relevant fluid anyway. For cortisol, the correlation with serum and saliva is reasonably good. For glucose it is weaker and more variable. For many novel biomarkers, the basic physiology of how the molecule gets into sweat has not been properly characterised. Large, rigorous studies that pair continuous sweat data with blood draws across diverse populations are still scarce, and without them regulators will not accept sweat readings as clinically actionable.

Durability and manufacturability. The 21-day UC Irvine result is a breakthrough precisely because so few devices had managed more than a day. But moving from a hand-assembled prototype to millions of identical, low-cost, shelf-stable patches with enzyme or antibody coatings that survive shipping and storage is a formidable engineering and quality problem. Continuous glucose monitors took well over a decade to get there.

Regulation. Hydration patches for athletes sit comfortably in the wellness category. A patch that claims to detect kidney dysfunction or guide hormone therapy is a medical device, and will need clinical evidence, quality systems and post-market surveillance. Companies will need to decide early which side of that line they intend to operate on. The most successful wearable businesses of the past decade, from Oura to Whoop, have largely stayed on the wellness side while building datasets that later support clinical claims. Sweat sensor companies will likely follow the same route, launching first in sport, occupational safety and consumer wellness, then moving into regulated indications as their evidence base grows.

Data, privacy and interpretation. A patch that streams cortisol, glucose and kidney markers to a phone creates a stream of sensitive health data that will attract regulators and, potentially, insurers and employers. It also creates an interpretation problem. A single elevated reading means little; what matters is the pattern over time relative to the individual's baseline. That is fundamentally a software and machine learning challenge, and it is where a great deal of the value will sit.

The commercial landscape

The market for dedicated wearable sweat analysis devices is still small. One recent estimate puts it at just under $80 million US dollars in 2025, growing at more than 30 per cent a year to over 1.4 billion dollars by 2035, with patches the dominant format and glucose the largest single analyte category. Those numbers should be treated with the usual caution, but the direction is not in doubt.

Several forces are pushing the same way. Preventive and personalised medicine are shifting healthcare spending towards continuous monitoring. Health systems everywhere are under pressure to move diagnosis and chronic disease management out of hospitals and into homes. The consumer wearables market has trained hundreds of millions of people to wear sensors and look at their own data every day. And the incumbent giants of that market, from Apple and Samsung to Garmin and Google, are actively searching for the next metric beyond heart rate, oxygen saturation and sleep. Biochemical sensing is the obvious candidate, and sweat is the only non-invasive route to it.

Expect three kinds of companies to matter. Specialist sweat sensor firms, many spun out of the leading university laboratories at Caltech, Northwestern, Berkeley, UC Irvine, Cincinnati and elsewhere, will supply the core sensing technology. Consumer wearable brands will license or acquire that technology and integrate it into rings, watches and patches. And medical device and diagnostics companies, including the continuous glucose monitoring incumbents, will either build or buy their way into sweat-based products to defend and extend their franchises. The pattern of licensing, partnership and acquisition that played out in continuous glucose monitoring and in optical heart-rate sensing is very likely to repeat.

The wildcard is which analyte becomes the "killer app". Hydration got there first because it was easy and had a ready market in sport. Stress hormones may be next, because they are hard to measure any other way and the demand from mental health, occupational safety and performance is enormous. Glucose is the biggest prize but the hardest to win. And the disease-detection applications, if they can be validated, would be transformative but are furthest from market.

What a sweat monitored future might look like

Picture a small, transparent patch on the inside of the forearm, changed once every few weeks. It generates a tiny trickle of sweat on its own, so it works while you sleep or sit in meetings. It reads sodium, lactate, glucose, cortisol, urea and a handful of other markers every few minutes, corrects for temperature and sweat rate, and sends the results to your phone.

Over the first month it learns your baselines and rhythms. After that, it mostly stays quiet. It tells you when you have not drunk enough on a hot day, and how much to drink. It notices that your cortisol has stopped falling at night during a hard stretch at work and suggests something be done about it before it turns into something worse. It shows your doctor a three-month trend in your kidney marker that would never have been caught by an annual blood test. It helps a woman time fertility treatment without daily clinic visits, and helps a person with early metabolic disease see, in real time, how their choices are changing their chemistry.

None of that is science fiction. Each individual element has been demonstrated in a peer-reviewed study within the last three years. What remains is integration, validation, manufacturing and regulation, and those are problems that the medical technology industry knows how to solve when the prize is large enough.

Conclusion

For a century, the body's chemistry has been something we sampled occasionally, painfully and expensively. Sweat sensors offer a way to read it continuously, painlessly and cheaply, from the surface of the skin. The latest generation of devices, wireless, battery-free, multiplexed, self-calibrating and now capable of running for weeks, has moved the field from proof of concept to the threshold of real products.

The road from here runs through the unglamorous work of clinical validation, manufacturing scale-up and regulatory approval, and through the harder science of understanding exactly how each molecule gets from blood to sweat. But the destination is clear.

Hydration, stress, fatigue, metabolic health and disease surveillance are all within reach of the same small patch. When it arrives, the idea that you once had to be stuck with a needle to find out what was happening inside your own body will seem as quaint as the idea that you once had to visit a doctor to learn your heart rate.

Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #MedTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada #Commonwealth #CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics